I am a gastrointestinal (GI) oncologist who takes care of patients with all types of GI cancer except primary liver cancers. As physician-in-chief at the OSUCCC – James, I have the privilege of leading a medical staff of more than 140 surgical, medical and radiation oncologists. I am also associate director for the cancer center’s outreach programs.
My clinical interests include colorectal and other GI cancers, carcinoid and GI tract neuroendocrine tumors, drug development and inherited predisposition to GI cancers. I help design, complete and analyze clinical studies involving patients with GI cancers (principally colorectal), translational studies with laboratory collaborators on biologic specimens from patients with cancer, and studies on the development of drugs and drug combinations. My research specialty is colorectal cancer; I have helped design and manage many large international clinical trials that have improved cure rates for patients with early-stage disease and survival times for patients with advanced disease.
For example, I led an international phase III study that compared oxaliplatin, irinotecan and 5-fluorouracil drug combinations for first-line treatment of patients with advanced colorectal cancer. This study, which led to FDA approval of oxaliplatin for clinical use, helped change the standard of care for these patients.
Nationally, I serve as associate group chair for cancer center affairs for the Alliance for Clinical Trials in Oncology. I am also chair and CEO of a French/U.S. charitable foundation called ARCAD (Aide et Recherche en Cancerologie Digestive), and co-chair of the Society of Translational Oncology.
American Board of Internal Medicine
American Board of Internal Medicine (Subspecialty: Medicine Oncology)
Lombardi Cancer Center, Georgetown University
7/1/1982 - 6/30/1984
Emory University Hospital
7/1/1980 - 6/30/1982
SUNY Upstate Medical University